Tavaborole, sold under the brand name Kerydin, is a topical antifungal medication for the treatment of onychomycosis, a fungal infection of the nail and nail bed with a complete clearance rate of 6-7% and partial clearance rate of 23-24% in individuals whose “infection border does not reach the cuticle at the base of the large toenail.”[1] Tavaborole was approved by the US FDA in July 2014.[2] The medication inhibits an essential fungal enzyme, leucyl-tRNA synthetase, that is required for protein synthesis. The inhibition of protein synthesis leads to termination of cell growth and then cell death, eliminating the fungal infection.
^Cite error: The named reference :0 was invoked but never defined (see the help page).
^"FDA Approves Anacor Pharmaceuticals' KERYDIN™ (Tavaborole) Topical Solution, 5% for the Treatment of Onychomycosis of the Toenails". Market Watch. July 8, 2014.
Tavaborole, sold under the brand name Kerydin, is a topical antifungal medication for the treatment of onychomycosis, a fungal infection of the nail and...
rapidly withdrawn from the European market (March 2020 - February 2022). Tavaborole – a structurally related topical antifungal developed by Anacor "FDA Approves...
alone. Although eficonazole, P-3051 (ciclopirox 8% hydrolacquer), and tavaborole are effective at treating fungal infection of toenails, complete cure...
translation process. A common example of this class of antifungal is Tavaborole. Onychomycosis Benzoxaborole antifungal is for the treatment of onychomycosis...
arthritis, though none have as yet been generally approved for the purpose. Tavaborole (marketed as Kerydin) is an Aminoacyl tRNA synthetase inhibitor which...
even eliminate the transmission of African trypanosomiasis in humans. Tavaborole Jacobs RT, Nare B, Wring SA, Orr MD, Chen D, Sligar JM, et al. (June 2011)...
Global Information
